Why Ankylosing Spondylitis Is Often Misdiagnosed or Diagnosed Late and How Early Detection Could Change Long-Term Patient Outcomes

Ankylosing Spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, poses significant diagnostic challenges that often result in misdiagnosis or delayed diagnosis. Characterized by symptoms such as persistent lower back pain, stiffness, and reduced mobility, AS belongs to the broader category of axial spondyloarthritis (axSpA). It affects approximately 0.1% to 1.4% of the global population, with a higher prevalence in men, though recent studies highlight underdiagnosis in women. The average diagnostic delay ranges from 7 to 10 years, during which irreversible damage can occur.

Reasons for Misdiagnosis and Late Diagnosis

One primary reason Ankylosing Spondylitis is often misdiagnosed or diagnosed late is the insidious onset and non-specific nature of its symptoms. AS typically begins in young adulthood, with chronic low back pain and morning stiffness that improves with exercise but worsens with rest. These symptoms mimic common musculoskeletal issues like mechanical back pain, lumbar strain, or even fibromyalgia, leading primary care physicians or orthopedists to overlook AS. Patients may experience fatigue, low-grade fever, and weight loss, which can be attributed to infections or other systemic conditions, further delaying suspicion of AS. The slow progression means that early radiographic changes, such as sacroiliac joint erosion, may not be visible on standard X-rays, requiring advanced imaging like MRI or CT for confirmation.

Gender differences exacerbate diagnostic delays, particularly in women. Historically, AS has been viewed as a “man’s disease,” with research predominantly involving male participants, resulting in diagnostic criteria biased toward male presentations. Women often exhibit slower progression of spinal damage detectable on X-rays and higher involvement of peripheral joints, such as arms and legs, rather than the classic lower back stiffness seen in men. Inflammatory markers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be lower in women, making blood tests less indicative. Consequently, women face an average diagnostic delay of 11 years compared to 5 years for men, frequently being misdiagnosed with conditions like fibromyalgia or osteoporosis. This bias stems from both physiological differences and healthcare disparities, where women’s pain is sometimes dismissed or attributed to psychological factors.

Diagnostic challenges also arise from the absence of a single definitive test. While the HLA-B27 gene is associated with AS, its presence is not universal—up to 20-30% of patients are HLA-B27 negative—and many carriers never develop the disease. Diagnosis relies on a combination of clinical history, physical examination (e.g., assessing spinal mobility and chest expansion), imaging, and lab tests for inflammation. However, early-stage AS may show no radiographic evidence, classified as non-radiographic axSpA, which complicates confirmation. Overlapping symptoms with other rheumatic diseases, such as psoriatic arthritis or rheumatoid arthritis, lead to misdiagnosis, especially if extra-articular manifestations like uveitis or psoriasis are present.

Healthcare system factors contribute to delays as well. Patients often see multiple providers before referral to a rheumatologist, with misdiagnoses commonly occurring in primary care or orthopedic settings. Low awareness among general practitioners, coupled with limited access to specialists in rural areas, prolongs the diagnostic journey. Factors like younger age at onset, negative HLA-B27 status, and comorbidities such as enthesitis or low educational levels are independently associated with longer delays.

Consequences of Late Diagnosis

The ramifications of delayed diagnosis are profound, allowing unchecked inflammation to cause irreversible structural damage. Prolonged disease activity leads to ankylosis (fusion) of vertebrae, resulting in kyphosis, restricted mobility, and increased fracture risk. Functional limitations affect daily life, with 10-30% of patients experiencing work disability after a decade. Extra-articular complications, including restrictive lung disease, ocular issues, and osteoporosis, become more prevalent, worsening prognosis.

How Early Detection Could Change Long-Term Outcomes

Early detection of Ankylosing Spondylitis transforms patient trajectories by enabling timely intervention that halts progression and preserves function. With diagnosis within the first few years of symptoms, treatments like non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and biologics (e.g., TNF-α inhibitors or IL-17 inhibitors) can be initiated promptly, leading to symptom remission and reduced inflammation. Studies show that early use of TNF-α inhibitors increases the likelihood of achieving significant clinical improvements, such as a 40% response on the Assessment of SpondyloArthritis International Society (ASAS40) criteria, by up to five times in patients with shorter symptom duration.

Preventing radiographic progression is a key benefit. Early treatment slows structural damage to the spine and sacroiliac joints, as evidenced by reduced changes on MRI and X-rays in trials of drugs like secukinumab and ixekizumab. For instance, prolonged anti-TNF therapy over four years in early non-radiographic axSpA patients demonstrates low progression rates, maintaining joint integrity and mobility. This contrasts with late diagnosis, where fusion and deformity are often advanced, limiting treatment efficacy.

Quality of life improvements are substantial with early detection. Patients experience better pain control, enhanced physical function, and reduced disability, allowing continued employment and social engagement. Early intervention also mitigates extra-articular manifestations, decreasing risks of uveitis or cardiovascular complications associated with chronic inflammation. Screening models, such as those reducing diagnostic delay from 9 years to shorter periods, facilitate this by integrating MRI early and raising awareness among providers.

Moreover, early diagnosis empowers patients through education and lifestyle modifications, including exercise regimens that preserve flexibility. In women, addressing gender biases in diagnostics could equalize outcomes, preventing prolonged suffering. Overall, early detection shifts AS from a debilitating condition to a manageable one, with data indicating sustained efficacy and improved patient-reported outcomes.

Strategies to Promote Early Detection

To achieve these benefits, strategies must include increased education for healthcare providers on AS red flags, such as inflammatory back pain in young adults. Utilizing MRI for suspected cases without radiographic evidence and genetic testing for HLA-B27 in high-risk groups can expedite diagnosis. Public awareness campaigns and streamlined referral pathways to rheumatologists are essential, particularly for underserved populations.

Summary

The frequent misdiagnosis or late diagnosis of Ankylosing Spondylitis stems from its subtle onset, gender disparities, and diagnostic complexities, leading to irreversible damage and diminished quality of life. However, early detection revolutionizes outcomes by enabling effective treatments that prevent progression, reduce complications, and enhance functionality. By prioritizing awareness, advanced imaging, and equitable care, healthcare systems can bridge this gap, transforming AS management and offering patients a brighter future.

Advertisement:

No products found.